CSS
CAPR icon

Cubist Systematic Strategies’s Capricor Therapeutics CAPR Stock Holding History

Cubist Systematic Strategies’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,268
Closed -$368K – 3061
2024
Q1 		$368K Buy
+54,268
New +$262K ﹤0.01% 2780
2023
Q1 		– Sell
-29,387
Closed -$113K – 3939
2022
Q4 		$113K Buy
29,387
+6,432
+28% +$30.7K ﹤0.01% 3773
2022
Q3 		$138K Buy
+22,955
New +$117K ﹤0.01% 3910

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Cubist Systematic Strategies's CAPR Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Capricor Therapeutics (CAPR) in Q2 2024, closing a stake of 54,268 shares — an estimated $368K sold.

Cubist Systematic Strategies first reported a position in CAPR in Q3 2022 and held it in 3 quarters. The position peaked at $368K in Q1 2024. 61 funds tracked by Wall St. Rank hold CAPR as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Capricor Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 54,268 Capricor Therapeutics shares in Q2 2024, an estimated $368K.
  • Cubist Systematic Strategies first reported a position in Capricor Therapeutics in Q3 2022 and held it in 3 quarters.
  • Cubist Systematic Strategies's Capricor Therapeutics position peaked at $368K in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.